公司简介
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...
关联新闻
- Mirum's liver infection drug lowers virus levels in late-stage study
Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.
- US FDA approves Mirum's drug for rare bone disorder
The US Food and Drug Administration has approved Mirum Pharmaceuticals' drug to treat a rare bone disorder, the regulator said on Friday.